1. Introduction {#sec1-materials-09-00464}
===============

Cutaneous squamous cell carcinoma (cSCC) derived from keratinocytes of the skin can be locally invasive or distantly metastatic \[[@B1-materials-09-00464],[@B2-materials-09-00464],[@B3-materials-09-00464]\]. cSCC is the leading fatal cause in non-melanoma skin cancers \[[@B1-materials-09-00464],[@B3-materials-09-00464],[@B4-materials-09-00464]\] and the second most common skin cancer, accounting for 15%--25% of all cutaneous malignancies \[[@B1-materials-09-00464],[@B5-materials-09-00464],[@B6-materials-09-00464]\]. Approximately 250,000 cSCCs are diagnosed annually in the United States and the incidence is still increasing \[[@B1-materials-09-00464],[@B7-materials-09-00464]\]. Mortality from cSCC is usually due to metastasis \[[@B1-materials-09-00464],[@B5-materials-09-00464],[@B8-materials-09-00464]\] and the survival rate has not declined in decades \[[@B9-materials-09-00464]\]. Some hypotheses for the carcinogenesis of cSCC have been proposed \[[@B2-materials-09-00464],[@B6-materials-09-00464],[@B10-materials-09-00464]\], but the actual etiology and carcinogenesis of cSCC remains unclear \[[@B11-materials-09-00464],[@B12-materials-09-00464]\].

cSCC represents a classic model of somatic mutation and a fundamentally genetic disease with highly individualized genetic etiology \[[@B13-materials-09-00464],[@B14-materials-09-00464]\]. The Ion Torrent Personal Genome Machine (Ion PGM), a next generation sequencing technology, has revolutionized genetic and genomic research with the comprehensive analysis of genomes, transcriptomes and interactomes \[[@B15-materials-09-00464],[@B16-materials-09-00464]\]. Based on semiconductor sequencing technology that detects electrical signals directly on a disposable chip, Ion PGM has the advantages of high accuracy, speed and affordability \[[@B17-materials-09-00464],[@B18-materials-09-00464]\]. To date, little is known about the utilization of Ion PGM in cSCC. In this study, we investigated the mutational patterns of the key genes in cSCC by Ion PGM, pyrosequencing and Sanger sequencing.

2. Results {#sec2-materials-09-00464}
==========

2.1. Demographic Data {#sec2dot1-materials-09-00464}
---------------------

We included 67 cSCC specimens from patients of ages ranging from 44 to 93 years (mean age: 73.9 years old) and of both sexes (female: 29; male: 38). Of the 67 tumors, 51 (76.1%) were from patients of advanced age, and 16 (23.9%) were from patients below 65 years old. Forty-two (62.7%) specimens came from sun-exposed sites and 25 (37.3%) came from non-sun-exposed sites. Eighteen (26.9%) of the specimens were larger than 2 cm, and six (9%) had deep invasion with Clark level IV. The ratios of histopathological grading were nine (13.4%) well differentiated, 39 (58.2%) moderately differentiated, and 19 (28.4%) poorly differentiated. There were three (4.5%) cases with distal metastasis and seven (10.4%) with recurrence. We assigned risk according to the American Joint Committee on Cancer staging manual, 7th Edition (AJCC-7), with risk features including tumor diameter 2 cm, Clark level IV, tumor thickness \>2 mm, location on ear or non-hair-bearing (vermillion) lip, poorly differentiated histologic finding for the first time, and perineural invasion \[[@B1-materials-09-00464]\]. Thirty-seven (55.2%) were designated as high-risk cSCCs, and 30 (44.8%) were low risk ([Table 1](#materials-09-00464-t001){ref-type="table"}).

2.2. Target Variants of High-Risk cSCC Using Ion Torrent Personal Genome Machine {#sec2dot2-materials-09-00464}
--------------------------------------------------------------------------------

Among the high-risk cSCCs, two specimens were microdissected and analyzed for driver gene mutations using a panel covering 739 mutations in 46 cancer-related genes (Ion AmpliSeq Cancer Panel, Life Technologies, Carlsbad, CA, USA). In patient one, 14 different mutations were observed in 11 cancer-related genes. Among these mutations, seven were missense mutations and the rest were silent mutations ([Table 2](#materials-09-00464-t002){ref-type="table"}). In patient two, 14 different mutations were observed in 12 cancer-related genes. Among these mutations, seven were missense mutations and the rest were silent mutations ([Table 3](#materials-09-00464-t003){ref-type="table"}). Five of the seven missense mutations were found in both patients one and two: a KDR mutation (Chr. 4; g. 55972974 T \> A); an EGFR mutation (Chr. 7; g. 55249110 G \> A); two FGFR2 mutations (Chr. 10; g. 123274818 T \> A and g. 123274819 T \> C); and a HNF1A mutation (Chr. 12; g. 121432011G \> C). Based on the above results, four target oncogenes (KDR, EGFR, FGFR2, and HNF1A) from the two high-risk cSCC patients were subsequently confirmed for the presence of missense gene mutations with pyrosequencing and Sanger sequencing.

2.3. Mutation Prevalence in cSCC According to Tumor Risk {#sec2dot3-materials-09-00464}
--------------------------------------------------------

Target genes' missense mutations (KDR, EGFR, FGFR2 and HNF1A) were detected by PCR in 67 microdissected cSCC samples. We used pyrosequencing to detect EGFR g. 55249110 G \> A and FGFR2 g. 123274818 T \> A mutations in 22 (32.8%) and 28 (41.8%) of the cSCC samples ([Figure 1](#materials-09-00464-f001){ref-type="fig"}), respectively. Simultaneously, No FGFR2 g. 123274819 T \> C mutant was found in this study by pyrosequencing. In addition, the KDR g. 55972974 T \> A mutant was validated by Sanger DNA sequencing ([Figure 2](#materials-09-00464-f002){ref-type="fig"}). Our results indicated a mutation rate of 61.2% (41/67) in cSCC. Among 41 patients, 14 were homozygous (14/41; 33.3%) and 27 were heterozygous mutations (27/41; 66.7%), respectively. These results indicate that the mutation screen by Ion PGM is consistent with the traditional sequencing method. However, the FGFR2 g. 123274819 T \> C mutant was not detected by pyrosequencing, nor was the HNF1A mutation detected by pyrosequencing and Sanger sequencing.

The FGFR2 mutation existed at a higher frequency in older patients with cSCC (*p* = 0.032). There were no statistically significant differences in gender, location, histopathological differentiation and metastasis for KDR, FGFR2 and EGFR mutations. Among the high-risk cSCCs, KDR, FGFR2, and EGFR mutations were detected in 72% (*p* = 0.028), 59% (*p* = 0.001), and 57% (*p* \< 0.001) of high-risk cSCC, respectively ([Table 4](#materials-09-00464-t004){ref-type="table"}). According to the above results, the KDR g. 55972974 T \> A occurred with the highest proportion. Although the FGFR2 and EGFR mutant rates are low, we consider that these mutations play some role in the tumors of older and high-risk cSCC patients. Additionally, the HNF1A mutation is most likely a sequencing artifact from the AmpliSeq Cancer HotSpot panel, as this variant is located at the end of the amplicon and is present at low frequency.

3. Discussion {#sec3-materials-09-00464}
=============

The Ion Torrent Personal Genome Machine (Ion PGM) is a high-throughput DNA sequencing breakthrough, with applications beyond the conventional genomic sequencing which originally spurred its development \[[@B15-materials-09-00464],[@B19-materials-09-00464],[@B20-materials-09-00464]\]. This next generation sequencing technology provides rapid methods for genome-wide characterization and profiling of mRNAs, transcription factor regions, chromatin structure, metagenomics, and microbiology \[[@B15-materials-09-00464],[@B19-materials-09-00464],[@B21-materials-09-00464],[@B22-materials-09-00464],[@B23-materials-09-00464]\]. Ion PGM is unlike other conventional next-generation sequencing systems, which use dyes to label nucleotides and must be optically read via fluorescence imaging \[[@B17-materials-09-00464],[@B24-materials-09-00464]\]. Ion PGM detects electrical signals directly on a semiconductor chip and reads nucleotides by sensing the pH value variation during complementary strand synthesis \[[@B17-materials-09-00464],[@B24-materials-09-00464]\]. Whereas most sequencing techniques available nowadays take a week to process DNA samples, the Ion PGM analyzes sequences in a matter of hours \[[@B17-materials-09-00464],[@B18-materials-09-00464]\]. It has surpassed traditional approaches in terms of economy, speed, and accuracy and offers comprehensive genetic information \[[@B15-materials-09-00464],[@B19-materials-09-00464]\]. With shortened sequencing time, 99% accuracy \[[@B17-materials-09-00464],[@B24-materials-09-00464]\], and decreased experiment costs, sequencing has become affordable for more labs and researchers, resulting in an ever-increasing array of applications \[[@B20-materials-09-00464],[@B24-materials-09-00464]\].

Skin cancers involve individualized genetic etiologies with somatic alterations that underlie mosaicism \[[@B13-materials-09-00464],[@B21-materials-09-00464],[@B25-materials-09-00464],[@B26-materials-09-00464]\]. In the past years, several genes have been considered for association with cSCCs, but genes scattered within genomes with low prevalence are difficult to detect by traditional molecular methods \[[@B13-materials-09-00464],[@B27-materials-09-00464],[@B28-materials-09-00464]\]. Deep sequencing by next generation techniques can now probe heavily mutagenized genomes with large numbers of low-frequency mutations characteristic of skin cancers \[[@B13-materials-09-00464]\]. To the best of our knowledge, this study is the first use of Ion PGM to reveal gene mutations in high-risk cSCCs. High-risk cSCCs are characterized by tumor size \>2.0 cm, high histological grade and localization on the ear or lip, deep and perineural invasion, recurrence, immunosuppression, and arsenic toxicity, usually with additional unfavorable prognoses and poor outcome \[[@B1-materials-09-00464],[@B4-materials-09-00464],[@B5-materials-09-00464],[@B29-materials-09-00464],[@B30-materials-09-00464],[@B31-materials-09-00464]\]. Scientists suggest that highly mutagenized skin cancers may stimulate additional oncogenic pathways, such that combination strategies in targeted therapies may be required \[[@B13-materials-09-00464],[@B32-materials-09-00464],[@B33-materials-09-00464]\]. Early detection and development of target therapies for high-risk cSCC are imperative. Clarifying the genetic prospect of cSCC, especially the targets which have been generally sparse, would facilitate the development of targeted therapies for cSCC \[[@B9-materials-09-00464],[@B32-materials-09-00464]\].

The *KDR* gene encodes VEGFR-2, a receptor tyrosine kinase overexpressed in a variety of solid tumors \[[@B34-materials-09-00464]\]. *KDR* also is an important factor in tumor progression and development due to its pro-angiogenic effects \[[@B35-materials-09-00464]\]. Previous studies indicated that the *KDR* g. 55972974 T \> A (p.Q472H) mutant had increased VEGFR-2 protein phosphorylation and was associated with increased microvessel density (MVD) in non-small cell lung cancer (NSCLC) tumor specimens \[[@B36-materials-09-00464]\]. *KDR* p.Q472H was identified in 7/10 lung adenocarcinomas and 1/1 mixed NSCLC/SCLC \[[@B34-materials-09-00464]\]. The *KDR* p.Q472H variant also appears to play a role in melanoma progression \[[@B37-materials-09-00464]\]. In addition, the mutation *KDR* p.Q472H also was found in Hepatic carcinosarcoma \[[@B38-materials-09-00464]\]. Therefore, *KDR* p.Q472H is a common variant in various tumors. Our data also implicates the *KDR* p.Q472H variant in cSCC progression. This has not been reported before and suggests that further functional studies are warranted.

4. Materials and Methods {#sec4-materials-09-00464}
========================

4.1. Sample Collection {#sec4dot1-materials-09-00464}
----------------------

Sixty-seven Asian samples with a diagnosis of squamous cell carcinoma of the skin were obtained from the dermatological and pathologic files and tumor registry from the Department of Pathology, Chung Shan Medical University Hospital, Taiwan (2002--2012). Formalin-fixed paraffin-embedded (FFPE) tissues of cSCC were obtained from the Departments of Dermatology and Pathology, Chung Shan Medical University Hospital, Taiwan. All histological sections were reviewed and the diagnoses were confirmed by the dermatologist and pathologist. Clinical information was extracted from medical records ([Table 1](#materials-09-00464-t001){ref-type="table"}). The study was approved by the Chung Shan Medical University Hospital (IRB No. CS12159) institutional review board. All tumors had been previously analyzed for next-generation sequencing and status.

4.2. Genomic DNA Purification and Quantification {#sec4dot2-materials-09-00464}
------------------------------------------------

Genomic DNA was extracted from tissues after enrichment for neoplastic cellularity, using manual microdissecion, and then processed with High Pure PCR Template Preparation Kit (Indianapolis, IN, USA). Quantitation of DNA was done using a Nanodrop 1000 spectrophotometer (Thermo Scientific Nanodrop Technologies, Wilmington, NC, USA).

4.3. Ion Torrent Personal Genome Machine {#sec4dot3-materials-09-00464}
----------------------------------------

Ten nanograms of DNA was used for multiplex PCR of a panel covering 739 mutations in 46 cancer-related genes (Ion AmpliSeq Cancer Panel, Life Technologies). Library construction of the amplicons and subsequent enrichment of the sequencing beads were performed according to the manufacturer's protocol. While the sequencing run, the sample cSCC 1 had a coverage 2356 with 472,908 reads, and the sample cSCC 2 had a coverage 2374 with 482,928 reads. Sequencing was done on the 314 chip using the Ion Torrent Personal Genome Machine (Life Technologies) as per the manufacturer's protocol. Data analysis, including alignment to the hg19 human reference genome and base calling, was done using built-in software v2.2.

4.4. Sequencing {#sec4dot4-materials-09-00464}
---------------

DNA extracted from the microdissected fresh-frozen skin cancers, pre-skin cancers and normal epidermis was subjected to whole genome amplification using Repli G (Qiagen, Germantown, OH, USA) and used in PCR as a template for specific primer sets ([Figure 3](#materials-09-00464-f003){ref-type="fig"}) designed to amplify the target genes. DNA extracted from skin cancers was also amplified in PCR without undergoing prior whole genome amplification. PCR products were purified using ExoSap and used directly in Sanger sequencing with BigDye v3.1 and the Applied Biosystems 3730 sequencer for KDR and in pyrosequencing with the PyroMark sequencer for EGFR and FGFR2.

4.5. Statistical Analysis {#sec4dot5-materials-09-00464}
-------------------------

All experiments were performed and presented as means ± SD. Statistical analyses were performed using one-way analysis of variance (ANOVA) followed by Tukey's *post-hoc* test (SPSS 17.0 software) to determine significant differences among the groups. The difference was considered significant when *p* \< 0.05.

5. Conclusions {#sec5-materials-09-00464}
==============

In conclusion, we identified gene mutations in cSCC using personalized Ion Torrent technology. Furthermore, KDR, FGFR2, and EGFR gene mutations were found in high-risk cSCC, suggesting that these mutations could be potential therapeutic targets for cSCC treatment.
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![EGFR and FGFR2 mutations were validated by pyrosequencing of cSCC specimens. (**a**) EGFR g. 55249110 G \> A (**b**) FGFR2 g. 123274818 T \> A. Both (**a**,**b**) are reverse sequences.](materials-09-00464-g001){#materials-09-00464-f001}

![KDR mutation (g. 55972974 T \> A) was validated by Sanger DNA sequencing of cSCC specimens: (**a**) heterozygous mutation (**b**) homozygous mutation.](materials-09-00464-g002){#materials-09-00464-f002}

![Specific primers for KDR, EGFR, and FGFR2 were used in this study: (**a**) primers for KDR mutation; (**b**) primers for mutation variant; (**c**) primers for FGFR2 mutation.](materials-09-00464-g003){#materials-09-00464-f003}

materials-09-00464-t001_Table 1

###### 

Demographic and histopathological data of cutaneous squamous cell carcinoma patients.

  Characteristics   No. of Patients   Percentage   Characteristics   No. of Patients   Percentage
  ----------------- ----------------- ------------ ----------------- ----------------- ------------
  Age               \-                \-           Differentiation   \-                \-
  \<65              16                23.9         Poor              19                28.4
  ≧65               51                76.1         Moderate          39                58.2
  Sex               \-                \-           Well              9                 13.4
  Male              38                56.7         Recurrence        \-                \-
  Female            29                43.3         No                60                89.6
  Location          \-                \-           Yes               7                 10.4
  Face              28                41.8         Metastasis        \-                \-
  Ear and lip       14                20.9         No                64                95.5
  Others            25                37.3         Yes               3                 4.5
  Tumor size        \-                \-           Risk              \-                \-
  ≤2 cm             49                73.1         Low               30                44.8
  \>2 cm            18                26.9         High              37                55.2
  Clark level       \-                \-           \-                \-                \-
  \<IV              61                91.0         \-                \-                \-
  ≧IV               6                 9.0          \-                \-                \-

materials-09-00464-t002_Table 2

###### 

Target variants of high-risk cSCC no. 1 specimen.

  Chrom   Position    Gene Sym   Ploidy   Ref   Variant   VarFreq   Coverage   Ref Cov   Var Cov   AA Mut
  ------- ----------- ---------- -------- ----- --------- --------- ---------- --------- --------- ---------
  chr4    1807894     FGFR3      Hom      G     A         99.64     1652       6         1646      \-
  chr4    55141055    PDGFRA     Hom      A     G         99.92     4967       1         4963      \-
  chr4    55972974    KDR        Hom      T     A         99.87     3051       3         3047      p.Q427H
  chr5    112175770   APC        Hom      G     A         99.73     1472       4         1468      \-
  chr7    55249063    EGFR       Het      G     A         44.12     102        57        45        \-
  chr7    55249110    EGFR       Het      G     A         8.33      2160       1980      180       p.R803Q
  chr7    116339672   MET        Het      C     T         53.44     1106       514       591       \-
  chr7    116340262   MET        Het      A     G         51.56     3305       1598      1704      p.N375S
  chr10   43613843    RET        Het      G     T         51.06     47         23        24        \-
  chr10   123274818   FGFR2      Het      T     A         5.37      3797       3582      204       p.K367M
  chr10   123274819   FGFR2      Het      T     C         10.88     3905       3479      425       p.K367E
  chr11   108236046   ATM        Het      C     G         5.45      716        676       39        \-
  chr12   121432011   HNF1A      Het      G     C         4.38      3450       3292      151       p.G253A
  chr14   105246407   AKT1       Het      G     A         43.66     6439       3627      2811      \-

materials-09-00464-t003_Table 3

###### 

Target variants of high-risk cSCC no. 2 specimen.

  Chrom   Position    Gene Sym   Ploidy   Ref   Variant   Var Freq   Coverage   Ref Cov   Var Cov   AA Mut
  ------- ----------- ---------- -------- ----- --------- ---------- ---------- --------- --------- ---------
  chr3    178952190   PIK3CA     Het      C     A         7.42       1307       1209      97        \-
  chr4    1807894     FGFR3      Hom      G     A         99.67      1534       1         1529      \-
  chr4    55141055    PDGFRA     Hom      A     G         99.91      5433       4         5428      \-
  chr4    55152040    PDGFRA     Het      C     T         61.32      6981       2699      4281      \-
  chr4    55972974    KDR        Het      T     A         52.74      2300       1085      1213      p.Q427H
  chr5    112175770   APC        Hom      G     A         99.24      1964       14        1949      \-
  chr7    55249110    EGFR       Het      G     A         6.79       3227       3004      219       p.R803Q
  chr9    21971179    CDKN2A     Het      G     A         58.12      1194       499       694       p.A60V
  chr10   43613843    RET        Het      G     T         43.9       41         23        18        \-
  chr10   123274818   FGFR2      Het      T     A         5.94       4445       4169      264       p.K367M
  chr10   123274819   FGFR2      Het      T     C         11.02      4536       4027      500       p.K367E
  chr11   108236046   ATM        Het      C     G         5.01       659        624       33        \-
  chr12   121432011   HNF1A      Het      G     C         4.52       2743       2612      124       p.G253A
  chr13   48942722    RB1        Het      C     T         8.91       404        368       36        p.P370L

materials-09-00464-t004_Table 4

###### 

Target genes (KDR, FGFR2, EGFR) expressions in cSCC specimens (*n* = 67).

  Characteristics   No. of Patients   KDR        FGFR2      EGFR                                                                
  ----------------- ----------------- ---------- ---------- ----------- ---------- ---------- ----------- ---------- ---------- -----------
                                      Positive   Negative               Positive   Negative               Positive   Negative   
                    Total             *n*        *n*        *p*-value   *n*        *n*        *p*-value   *n*        *n*        *p*-value
  Age                                                       0.200                             0.032 \*                          0.174
  \<65              16                12         4                      3          13                     3          13         
  ≧65               51                29         22                     25         26                     19         32         
  Sex                                                       0.385                             0.154                             0.806
  Male              38                25         13                     13         25                     12         26         
  Female            29                16         13                     15         14                     10         19         
  Location                                                  0.721                             0.080                             0.241
  Sunexposure       42                25         17                     21         21                     16         26         
  Non-sunarea       25                16         9                      7          18                     6          19         
  Differentiation                                           0.963                             0.751                             0.268
  Poor              19                12         7                      11         8                      8          11         
  Moderate          39                23         16                     11         28                     12         27         
  Well              9                 6          3                      6          3                      2          7          
  Recurrence                                                0.820                             0.096                             0.001 \*
  No                60                37         23                     23         37                     16         44         
  Yes               7                 4          3                      5          2                      6          1          
  Metastasis                                                0.845                             0.379                             0.985
  No                64                39         25                     26         38                     21         43         
  Yes               3                 2          1                      2          1                      1          2          
  Risk                                                      0.028 \*                          0.001 \*                          \<0.001\*
  Low               30                14         16                     6          24                     1          29         
  High              37                27         10                     22         15                     21         16         

\* The difference was considered significant when *p* \< 0.05.
